Smoking Cessation Using Motivational Therapy and Varenicline

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00701896
Recruitment Status : Completed
First Posted : June 19, 2008
Last Update Posted : February 13, 2017
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Philip Diaz, The Ohio State University

June 17, 2008
June 19, 2008
February 13, 2017
June 2008
April 20, 2013   (Final data collection date for primary outcome measure)
To develop and evaluate a specialized smoking cessation intervention for the treatment of nicotine dependence in HIV-seropositive smokers. [ Time Frame: 48 Months ]
Same as current
Complete list of historical versions of study NCT00701896 on Archive Site
  • To examine the effects of smoking cessation on the course of lung function decline, the prevalence of respiratory symptoms and the occurrence/progression of emphysema in a cohort of HIV-seropositive individuals. [ Time Frame: 48 Months ]
  • To explore the effects of smoking cessation on the biology of alveolar macrophages obtained from HIV-seropositive individuals [ Time Frame: 48 Months ]
Same as current
Not Provided
Not Provided
Smoking Cessation Using Motivational Therapy and Varenicline
Smoking Cessation and the Natural History of HIV-Associated Emphysema
People that are infected with HIV appear to be especially susceptible to the adverse effects of cigarette smoking. The purpose of this study is to determine if quitting smoking by using a specialized smoking cessation treatment can prevent one from developing accelerated lung damage, particularly emphysema.
HIV-infected smokers are at increased risk for life-threatening diseases, such as pneumonia. To date, very little is known about the tobacco consumption characteristics of this at-risk population of smokers, but it has been well documented that they are at high risk for smoking-related co-morbidities. In addition, few effective cessation strategies have been described in HIV-infected populations. A specialized smoking cessation that combines recommendations from an existing scientifically-valid clinical guideline with Motivational Interviewing a new pharmacotherapeutic agent, may be an effective mechanism to apply to this vulnerable population of smokers. This initial, efficacy investigation has the potential to guide future treatment and research pertaining to tobacco cessation, respiratory illness and HIV.
Not Applicable
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Smoking
  • HIV Infections
  • Drug: Varenicline tartrate
    1 mMg tablet form; daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12.
    Other Name: Chantix
  • Drug: Nicotine Replacement Therapy
    Nicotine gum and nicotine patch
  • Other: Biological Control
    No treatment intervention only information and procedures.
  • Behavioral: Motivational Interview
    60 minute one-on-one Interview
  • Healthy Control - Non-smoking
    Healthy Control arm with 51 subjects who are HIV negative and do not smoke
    Intervention: Other: Biological Control
  • Healthy Control - Smoker
    Healthy Control arm, includes 50 subjects who are HIV negative and are smokers.
    Intervention: Other: Biological Control
  • Active Comparator: HIV Smoking Cessation Arm
    Includes up to 365 subjects who are HIV positive and initiate smoking cessation
    • Drug: Varenicline tartrate
    • Drug: Nicotine Replacement Therapy
  • Experimental: Motivational Intervention
    Includes up to 100 subjects who are HIV positive, do not wish to quit smoking but are willing to undergo one-on-one Motivational Intervention
    Intervention: Behavioral: Motivational Interview
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
June 20, 2013
April 20, 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. 18 years of age and older;
  2. diagnosis of HIV;
  3. self-reported smoking on a daily basis;
  4. provide informed written consent

Exclusion Criteria:

  1. persons with active psychosis or impaired mental status as judged by the clinic staff and confirmed with a Mini-Mental Status Exam)
  2. unable to understand spoken English
  3. age less than 18 years.
  4. pregnant women
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
R01HL090313 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Philip Diaz, The Ohio State University
Philip Diaz
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Philip T. Diaz, MD Ohio State University
Ohio State University
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP